Trials / Completed
CompletedNCT02392364
Variable Interval Versus Set Interval Aflibercept for DME
Treat and Extend Versus Dosing Every Eight Weeks With Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema (EVADE Study)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- California Retina Consultants · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the safety and efficacy of intravitreal Eylea injections at a set interval, versus a variable dosing schedule (likely longer than one month), based on a specific individual's disease progression. There will be approximately 50 men and women at least 18 years of age, diagnosed with type 1 or type 2 diabetes, taking part in this study at 5 locations in the United States.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Intravitreal Aflibercept Injection |
Timeline
- Start date
- 2015-04-15
- Primary completion
- 2018-11-15
- Completion
- 2018-11-15
- First posted
- 2015-03-19
- Last updated
- 2019-01-03
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02392364. Inclusion in this directory is not an endorsement.